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ung cancer is the leading cause of cancer mor-
tality in the United States.1 Adenocarcinoma is
the most common histologic subtype of lung
cancer and most frequently metastasizes to the brain,
bone, liver, and adrenal glands, respectively.2 Five-year
survival for stage IV nonsmall-cell lung cancer is
1%.3 Rarely, lung cancer may exhibit cutaneous
metastases.Fig 1. Computed tomography scan of the thorax: malig-
nant pleural effusion, involvement of the pectoralis major
muscle and sternocleidomastoid muscle, and a 1.8- 3 1.4-
cm subcutaneous nodule in the right subareolar region.CASE REPORT
A 63-year-old man with stage IV pulmonary
adenocarcinoma presented with shortness of breath,
weakness, and a 3-month history of a rash on his
right chest. Prior positron emission/computed
tomography scan demonstrated hilar, mediastinal,
neck, and axillary adenopathy along with brain
metastasis. He had received whole brain radiation
and 6 cycles of carboplatin and pemetrexed. He
recently had 2 episodes of pneumonia, and 10 days
before this presentation, he had been found to have
a pulmonary embolism and rivaroxaban was started.
On admission, a chest x-ray revealed a right-sided
pleural effusion. A computed tomography scan
showed a stable right upper lung mass, progressive
metastatic disease, a growing malignant pleural
effusion, and muscular and subcutaneous involve-
ment. Involvement of the pectoralis major muscle
and sternocleidomastoid muscle along with a
1.8- 3 1.4-cm subcutaneous nodule in the right
subareolar region was seen (Fig 1).
A right axillary node biopsy specimen demon-
strated poorly differentiated carcinoma, which wasthe Baylor College of Medicine, Houstona; and Division
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own522@gmail.com.negative for epidermal growth factor receptor gene
mutation, signifying the cells lacked this transmem-
brane protein that is typically present in over half of
nonsmall-cell lung cancers,4 and negative for
anaplastic lymphoma kinase gene rearrangement,
which is seen in roughly 4% of nonsmall-cell lung
cancers, most frequently adenocarcinomas.5 Both
epidermal growth factor receptor gene mutations
and anaplastic lymphoma kinase gene rearrange-
ments, when present, are therapeutic targets. A
therapeutic and diagnostic thoracentesis was
conducted, and 2.1 L of pleural fluid were removed.
The level of lactate dehydrogenase in the pleura
fluid was 261, meeting Light criteria for classification
as an exudative pleural effusion, which is seen
in conditions such as infection, malignancy, orJAAD Case Reports 2015;1:378-80.
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Fig 2. Cutaneous findings. A, Erythematous, indurated, papillomatous plaques extending from
right shoulder to right side of trunk and flank. B, Lesions on right flank. C, Biopsied area on
right upper aspect of chest.
Fig 3. Histopathologic findings from skin overlying right upper aspect of chest. Atypical
epithelial cells in infiltrative tubular formations surrounded by fibromyxoid stroma. (A and
B, Hematoxylin-eosin stain; original magnifications: A, 32; and B, 320.)
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history, the exudative pleural effusion raised a high
level of suspicion for a malignant cause, which was
confirmed by cytologic studies that showed
metastatic adenocarcinoma.
Dermatologic examination was notable for
erythematous, indurated, papillomatous plaques
extending from his right shoulder to his entire right
trunk and flank (Fig 2). The rash was nonpainful,
nonpruritic, and had initially been thought to be a
drug rash.
A 4-mm punch biopsy specimen was taken of
the skin overlying the right side of his chest. There
were atypical epithelial cells in infiltrative tubular
formations associated with a fibromyxoid stroma
(Fig 3). The diagnosis of metastatic adenocarcinoma,
compatible with the patient’s known lung adenocar-
cinoma, was made.DISCUSSION
Theoverall incidenceof cutaneousmetastases from
internal malignancies is roughly 5.3%.6 This dissemi-
nation can occur through hematogenous, lymphatic,
direct or iatrogenic, spread.7 Of internal malignancies
with the tendency to metastasize to the skin, breast
cancer, in women, and lung cancer, in men, are the
most common origins.8 Rates of lung metastases to
skin have been estimated at 1.7% to 3%with a median
survival of less than 5 months.7,9 One study showed
that 0.3% of lung cancers are found initially after
cutaneous manifestations.6 Most lesions of cutaneous
lung metastases are asymptomatic, moveable, firm
nodules that are flesh-colored, pink, or violaceous.6,9
These lesions occur as solitary or multiple lesions.
There have been isolated cases of cutaneous meta-
stases from lung adenocarcinoma presenting as
carcinoma erysipeloides or carcinoma en cuirasse.10
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his thoracentesis. He was scheduled for outpatient
follow-up in the dermatology clinic for possible
radiation treatment if the cutaneous metastases
became symptomatic. However, he died within
2 weeks of his dermatologic diagnosis, which was
3.5 months from the initial development of his rash.
This case highlights the variation that can be
exhibited by cutaneous metastatic disease from
pulmonary adenocarcinoma. Nonpruritic, indurated
lesions in patients with a diagnosis of lung cancer
should always raise suspicion for cutaneous
metastases and undergo biopsy. Rarely, these lesions
may be the initial presentation of lung cancer.
Cutaneous metastases from lung cancer represent
advanced disease and are associated with a very poor
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